{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=12&state=Texas", "query": { "state": "Texas", "city": "Dallas", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 13766, "total_pages": 1377, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=13&state=Texas&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=11&state=Texas&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T05:57:38.369Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03442764", "title": "A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-obstructive Hypertrophic Cardiomyopathy" ], "interventions": [ { "name": "mavacamten", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MyoKardia, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2018-03-30", "completion_date": "2020-01-07", "has_results": true, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 32, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03442764" }, { "nct_id": "NCT00622466", "title": "Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2008-04-23", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00622466" }, { "nct_id": "NCT06915766", "title": "Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Systemic Mastocytoses, Indolent", "Systemic Mastocytoses, Aggressive" ], "interventions": [ { "name": "Bezuclastinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 23, "location_summary": "La Jolla, California • Los Angeles, California • Normal, Illinois + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Normal", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06915766" }, { "nct_id": "NCT01522456", "title": "Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Epiduo Gel", "type": "DRUG" }, { "name": "Retin-A Micro Microsphere 0.1%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2012-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2022-08-01", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522456" }, { "nct_id": "NCT02410356", "title": "Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Growth Hormone Deficiency" ], "interventions": [ { "name": "TV-1106", "type": "DRUG" }, { "name": "dGH", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2015-04-30", "completion_date": "2016-04-30", "has_results": false, "last_update_posted_date": "2021-12-10", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 32, "location_summary": "Artesia, California • Fountain Valley, California • Lakewood, California + 22 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Lakewood", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02410356" }, { "nct_id": "NCT06186622", "title": "A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Obese", "Overweight" ], "interventions": [ { "name": "Orforglipron", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Sodium Bicarbonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2024-01-02", "completion_date": "2024-07-10", "has_results": true, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 2, "location_summary": "Daytona Beach, Florida • Dallas, Texas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06186622" }, { "nct_id": "NCT03340831", "title": "Continuous Monitoring and Control of Hypoglycemia", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Continuous Glucose Monitoring (CGM)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "DexCom, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 1388, "start_date": "2017-10-20", "completion_date": "2023-12-30", "has_results": false, "last_update_posted_date": "2021-09-21", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 25, "location_summary": "La Jolla, California • La Mesa, California • Sacramento, California + 21 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Mateo", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03340831" }, { "nct_id": "NCT01644331", "title": "Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure", "Dyspnea" ], "interventions": [ { "name": "Tolvaptan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 257, "start_date": "2012-10", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-04-27", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 18, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Gainesville, Georgia + 14 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Gainesville", "state": "Georgia" }, { "city": "Macon", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644331" }, { "nct_id": "NCT05203939", "title": "Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Retinitis Pigmentosa", "Leber Congenital Amaurosis" ], "interventions": [ { "name": "OCU400 Low Dose", "type": "DRUG" }, { "name": "OCU400 Med Dose", "type": "DRUG" }, { "name": "OCU400 High Dose", "type": "DRUG" }, { "name": "OCU400 Second Eye Dosing", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocugen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 22, "start_date": "2022-01-24", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 7, "location_summary": "Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05203939" }, { "nct_id": "NCT00103428", "title": "Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "CG7870", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cell Genesys", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 69, "start_date": "2004-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-02-02", "last_synced_at": "2026-11-04T05:57:38.369Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103428" } ] }